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Lipocalin-type prostaglandin D synthase (L-PGDS) catalyzes
the isomerization of the 9,11-endoperoxide group of PGH2
(prostaglandin H2) to produce PGD2 (prostaglandin D2) with
9-hydroxy and 11-keto groups. The product of the reaction,
PGD2, is the precursor of several metabolites involved in
many regulatory events. L-PGDS, the ﬁrst member of the
important lipocalin family to be recognized as an enzyme, is
also able to bind and transport small hydrophobic molecules
and was formerly known as -trace protein, the second most
abundant protein in human cerebrospinal ﬂuid. Previous
structural work on the mouse and human proteins has focused
on the identiﬁcation of the amino acids responsible and the
proposal of a mechanism for catalysis. In this paper, the X-ray
structures of the apo and holo forms (bound to PEG) of
the C65A mutant of human L-PGDS at 1.40 A˚ resolution and
of the double mutant C65A/K59A at 1.60 A˚ resolution are
reported. The apo forms of the double mutants C65A/W54F
and C65A/W112F and the triple mutant C65A/W54F/W112F
have also been studied. Mutation of the lysine residue does
not seem to affect the binding of PEG to the ligand-binding
cavity, and mutation of a single or both tryptophans appears
to have the same effect on the position of these two aromatic
residues at the entrance to the cavity. A solvent molecule has
also been identiﬁed in an invariant position in the cavity of
virtually all of the molecules present in the nine asymmetric
units of the crystals that have been examined. Taken together,
these observations indicate that the residues that have been
mutated indeed appear to play a role in the entrance–exit
process of the substrate and/or other ligands into/out of the
binding cavity of the lipocalin.
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mutant, 4orw; 4orx; 4ory;
C65A/W54F mutant, 4os0;
C65A/W112F mutant, 4os3;
C65A/W54F/W112F mutant,
4os8
1. Introduction
The enzyme prostaglandin D synthase (or prostaglandin-H2
D-isomerase; PGDS; EC 5.3.99.2) catalyzes the isomerization
of the 9,11-endoperoxide group of PGH2 (prostaglandin H2)
to produce PGD2 (prostaglandin D2) with 9-hydroxy and
11-keto groups. PGH2, its substrate, is a common precursor
of all prostanoids, which include thromboxanes, prostacyclins
and prostaglandins, whereas the product PGD2 is the
precursor of several metabolites involved in many regulatory
events.
Two types of prostaglandin D synthase have been char-
acterized: haematopoietic PGDS (H-PGDS; Kanaoka &
Urade, 2003), which requires the cofactor glutathione (a
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tripeptide -glutamylcysteinyl glycine in which the thiol group
of cysteine is responsible for the biological activity), and
glutathione-independent or lipocalin-type PGDS (L-PGDS;
Urade & Hayaishi, 2000; Urade & Eguchi, 2002).
H-PGDS is a cytosolic enzyme whose highest levels of
expression are observed in spleen and bone marrow, in mast
cells, antigen-presenting cells and Th2 cells. It is the only
mammalian member of the sigma class of cytosolic glutathione
S-transferases (Flanagan & Smythe, 2011) and participates in
allergic and inﬂammatory reactions (Jowsey et al., 2001). Its
three-dimensional X-ray structure has been determined
(Kanaoka et al., 1997) and the amino-acid residues involved in
catalysis have been identiﬁed (Pinzar et al., 2000).
L-PGDS, the ﬁrst member of the important lipocalin family
to be recognized as an enzyme (Peitsch & Boguski, 1991), is
also able to bind and transport small hydrophobic molecules
including biliverdin, bilirubin, thyroid hormone (Beuckmann
et al., 1999), retinal and retinoic acid (Tanaka et al., 1997) and
may act as a scavenger for harmful hydrophobic ligands. A
systematic analysis of the interaction of hydrophobic ligands
with L-PGDS has been carried out using tryptophan ﬂuores-
cence quenching, induced circular dichroism and isothermal
titration calorimetry (Kume et al., 2012). The enzyme was
formerly known as -trace protein (Kuruvilla et al., 1991;
Hoffmann et al., 1993), the second most abundant protein
in human cerebrospinal ﬂuid, although it is also detected in
brain, testis and prostate, endothelial cells, placenta and heart
tissue and in macrophages inﬁltrated in atherosclerotic
plaques (Tanaka et al., 2009).
L-PGDS is involved in a variety of CNS functions such as
NREM (nonrapid eye movement) sleep (Jordan et al., 2004;
Qu et al., 2006) and allodynia, i.e. the perception of pain owing
to innocuous stimuli which do not normally evoke it (Eguchi et
al., 1999). It also appears to be a major endogenous amyloid
-chaperone in human cerebrospinal ﬂuid and in the brain and
thus it has been suggested that disturbance of this function
may be involved in the onset and progression of Alzheimer’s
disease (Kanekiyo et al., 2007). In general, it is believed to play
key roles in both the maturation and the maintenance of the
central nervous system and the male reproductive system
(Beuckmann et al., 2000; Samy et al., 2000). It is also over-
expressed in the bald scalp of men with androgenic alopecia
(Garza et al., 2012) and is used clinically as a diagnostic marker
for liquorrhoea, that is the outﬂow of cerebrospinal ﬂuid
leaking from the nose or ear (Bachmann et al., 2002).
NMR studies on mouse L-PGDS have established that the
protein indeed belongs to the lipocalin family (Shimamoto et
al., 2007) and X-ray structural work using crystals of the C65A
mutant, grown in the presence of retinoic acid as an essential
additive for crystallization, conﬁrmed that the overall struc-
ture of the core region of the -barrel in the crystals was
essentially identical to that in solution. Two conformers were
identiﬁed in the X-ray work: one with the central cavity open
and the other with the cavity closed. The large central cavity of
L-PGDS was found to be separated into two compartments by
several hydrophobic amino acids, with Cys65, which is known
to be essential for catalytic activity (Urade et al., 1995), located
in the upper compartment of the cavity (Kumasaka et al.,
2009). Structural studies on crystals of the C65A mutant of
human L-PGDS complexed with bound fatty acids further
explored the mode of ligand binding to the enzyme (Zhou et
al., 2010). Wild-type human L-PGDS was also crystallized and
studied by X-ray diffraction and the catalytic Cys65 thiol
group was found in two different conformations. Although
one of the crystal forms had been crystallized in the presence
of a substrate analogue, the electron density for the ligand
observed in the active site could only be used to deﬁne the
substrate-binding region of the enzyme; it did not allow the
unambiguous ﬁtting of the ligand in a single position (Lim et
al., 2013).
In the previous X-ray diffraction crystallographic work,
attention was focused on amino acids presumed to be involved
in catalysis. Here, we present studies of mutants of residues
of human L-PGDS that are believed to play a role in the
entrance/exit of the ligands to/from the central binding cavity.
2. Materials and methods
2.1. Construction of the mutants
The cDNA coding for human lipocalin-type prostaglandin
D synthase (L-PGDS; Image ID 4294999), obtained from
RZPD (Deutsches Ressourcenzentrum fu¨r Genomforschung
GmbH), was ampliﬁed by PCR using primers designed to
exclude the 22-amino-acid N-terminal signal peptide. The
PCR product and the expression vector pTYB1 (New England
Biolabs) were digested with the enzymes NdeI and SapI and
were incubated with ligase to insert the cDNA into the vector
respecting the open reading frame. The vector pTYB1
expresses the protein fused to the C-terminus of an intein/
chitin-binding domain tag, which is useful for the puriﬁcation
of the protein because the binding domain interacts with chitin
and intein self-cleaves in the presence of reducing thiols.
Site-directed mutagenesis to produce the C65A mutant was
performed by PCR using the QuikChange II site-directed
mutagenesis kit (Stratagene) with the wild-type construct as a
template. The mutant vector was then used as a template to
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Table 1
Primers used in the construction of the mutants.
The primers in the right-hand column introduce the mutation in bold in the
left-hand column.
Mutant Primers
C65A for: GCGTTGTCCATGGCCAAGTCTGTGGTG
rev: CACCACAGACTTGGCCATGGACAACGC
C65A/K59A (C65A) +
for: CTCCGGGAGAAGGCCGCGGCGTTGTCC
rev: GGACAACGCCGCGGCCTTCTCCCGGAG
C65A/W54F (C65A) +
for: TCCAACTCGAGCTTCCTCCGGGAGAAG
rev: CTTCTCCCGGAGGAAGCTCGAGTTGGA
C65A/W112F (C65A) +
for: CGGAGTCCCCACTTCGGCAGCACCTAC
rev: GTAGGTGCTGCCGAAGTGGGGACTCCG
C65A/W54F/W112F (C65A/W54F) +
for: CGGAGTCCCCACTTCGGCAGCACCTAC
rev: GTAGGTGCTGCCGAAGTGGGGACTCCG
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prepare the subsequent mutants. The primers used to intro-
duce all of the desired mutations are listed in Table 1. The
recombinant DNAs were fully sequenced to conﬁrm the
planned mutation and to ascertain that no spurious mutations
had occurred.
2.2. Overexpression and purification of the proteins
For the L-PGDS C65A and C65A/K59A mutants the
following protocol was used. BL21 (DE3) strain Escherichia
coli cells were transformed by heat shock with the resulting
vectors and grown in LB medium at 37C until an OD600 of 0.8
was reached; protein synthesis was then induced overnight
at 20C with 0.25 mM IPTG (isopropyl -d-1-thiogalactopyr-
anoside).
The bacterial cells were recovered by centrifugation at
8000g for 10 min and resuspended in 20 mM Tris–HCl pH 7.5,
0.5M NaCl, 1 mM EDTA for sonication. After centrifugation
at 10 000g for 10 min to remove debris, the soluble fraction
was loaded onto a chitin column equilibrated with the same
buffer. The presence of the intein tag allowed afﬁnity puriﬁ-
cation of the fused proteins by passing the bacterial extracts
through a chitin column. After extensive washing with 20 mM
Tris–HCl pH 7.5, 1.0M NaCl, 0.2% Tween 20 to remove
impurities, the column was equilibrated with 20 mM Tris–HCl
pH 7.5, 0.5M NaCl, 1 mM EDTA, 10 mM DTT and left at
20C overnight to allow intein cleavage. The eluted protein in
20 mM Tris–HCl pH 7.5, 0.5MNaCl, 1 mM EDTAwas further
puriﬁed by size-exclusion chromatography on a Superdex
G-75 (Pharmacia) column and by hydrophobic interaction
chromatography using Lipidex 1000 resin in a column
thermostated at 37C.
For the L-PGDS C65A/W54F, C65A/W112F and C65A/
W54F/W112F mutants a different protocol was used.
The mutants were prepared by inserting the mutated C65A
template into the pGEX4T-1 plasmid, which expresses the
protein with its N-terminus fused to glutathione S-transferase
(GST) through a thrombin-cleavage site. The recombinant
GST-fusion protein can be puriﬁed directly from the pre-
treated cell lysate by using a glutathione (GSH) Sepharose
resin. The tag-free target protein can then be recovered from
the column by digestion with thrombin followed by elution
with a standard buffer.
For protein expression the same BL21 (DE3) E. coli strain
and identical cell-growth and cell pre-treatment conditions
were used. The supernatant was loaded onto a GSH
Sepharose column previously equilibrated with 20 mM Tris–
HCl pH 7.5, 0.5M NaCl; after eliminating the contaminants,
30 units of thrombin were added to the column, which was left
to react overnight at 20C. The L-PGDS double and triple
mutants were recovered from the column with the Tris buffer
and further loaded onto a GSH Sepharose column to remove
traces of the chimeric uncleaved protein. A ﬁnal step of
hydrophobic interaction chromatography using Lipidex1000
resin was also carried out for the double mutants.
The protein concentrations were determined from the
speciﬁc extinction coefﬁcient at 280 nm and the purity and
molecular weight were assessed by SDS–PAGE with standard
molecular-weight markers.
2.3. Crystallization
The puriﬁed proteins were used at a concentration of about
25 mg ml1 for initial screening of crystallization conditions.
Molecular Dimensions Structure Screens were employed at
20C with the hanging-drop method, mixing 1 ml protein
solution (in 150 mM NaCl, 20 mM Tris–HCl buffer pH 7.5)
with the same volume of precipitating solution and equili-
brating against a volume of 0.3 ml of the latter in the reservoir.
The conditions yielding small crystals were later reﬁned and
the sitting-drop method with larger volumes was also tested
until crystals that were large enough for data collection were
obtained. The precipitating solutions that yielded crystals
suitable for X-ray diffraction are listed in Table 2. Diffraction-
quality crystals were obtained in about 4–5 d at 20C.
2.4. Data collection and processing
Preliminary data were collected on a MAR345 image plate
using radiation produced by a Rigaku RU-300 rotating-anode
X-ray generator. The incident X-ray beam was focused with
Xenocs multilayer confocal mirrors that selected Cu K
radiation. The ﬁnal data used for reﬁnement were collected
on various beamlines at the European Synchrotron Radiation
Facility (ESRF) in Grenoble. The diffraction data were
collected from crystals cooled to 100 K after brief immersion
into a mixture of 70% mother liquor and 30% glycerol. The
data were indexed, integrated and reduced using MOSFLM
(Leslie & Powell, 2007) and SCALA (Evans, 2006). The
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Table 2
Crystallization conditions.
Unit-cell parameters and data-collection statistics are given in Table 3.
Crystal
form Mutant
Space
group Reservoir solution
1 C65A P6122 0.1M Tris pH 7.0, 25% PEG 4000,
2% ethylene glycol
2 C65A P1 0.1M Na HEPES pH 7.5, 2% PEG 400,
2.0M ammonium sulfate
3 C65A P41 30% PEG 4000, 0.2M ammonium sulfate
pH 4.1
4 C65A/K59A P212121 0.1M Tris pH 8.5, 2.0M ammonium
phosphate
5 C65A/K59A P41 30% PEG 4000, 0.2M ammonium sulfate
pH 4.1
6 C65A/K59A P41 0.1M sodium acetate pH 4.6, 0.2M
ammonium sulfate, 30% PEG 2000
monomethyl ether
7 C65A/W54F P1 0.2M potassium sodium tartrate, 0.1M
sodium acetate pH 5.6, 2.0M ammonium
sulfate
8 C65A/W112F P1 (i) 0.1M sodium acetate, 2.0M ammonium
sulfate pH 4.6
(ii) 2.0M ammonium sulfate pH 5.9
(iii) 0.2M potassium sodium tartrate, 0.1M
sodium acetate pH 5.6, 2.0M ammonium
sulfate
9 C65A/W54F/
W112F
P1 0.1M sodium acetate, 2.0M ammonium
sulfate pH 4.6
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processed data were converted to structure factors using
TRUNCATE from the CCP4 suite (Winn et al., 2011).
A summary of the data-collection statistics is given in
Table 3.
2.5. Structure determination and refinement
The structure of the C65A mutant in the P6122 crystal form
was solved using the molecular-replacement method as
implemented in MOLREP (Vagin & Teplyakov, 2010). The
search probe used was monomer A of the complex of L-PGDS
with fatty acids, but with the ligands removed, solved at 1.7 A˚
resolution (Zhou et al., 2010; PDB entry 3o2y). The rotation
function gave an unambiguous answer with an Rf/ coefﬁcient
of 6.48. The highest peak of the translation function had a Tf/
of 22.52, a score of 61.8 and an R factor of 54.1 for the data in
the 29.6–1.7 A˚ resolution interval. Examination of the mole-
cular packing in the unit cell after rigid-body reﬁnement
showed that there were no clashes with the symmetry-related
molecules in this space group and conﬁrmed that the search
model was indeed properly oriented and positioned in the unit
cell. The C65A mutant in space group P1, the C65A mutant in
space group P41, the C65A/K59A double mutant in space
group P212121 and the octameric form of the C65A/K59A
double mutant in space group P41 were all solved by mole-
cular replacement using the reﬁned coordinates of the C65A
mutant model in space group P6122 as the search probe. All of
the other crystal forms listed in Table 3 are isomorphous to a
solved structure and therefore difference Fourier maps were
calculated directly with the experimental data and the phases
of the solved structure.
The initial models were ﬁrst reﬁned by simulated annealing
using phenix.reﬁne (Afonine et al., 2005; Davis et al., 2007)
from the PHENIX suite (Adams et al., 2010). The next step
was a series of several rounds of positional reﬁnement alter-
nated with manual model revision using Coot (Emsley et al.,
2010) and the reﬁnement programs REFMAC (Murshudov et
al., 2011) and phenix.reﬁne. During the process of reﬁnement
and model building the quality of the models was controlled
using PROCHECK (Laskowski et al., 1993).
The models were ﬁnally subjected to ﬁnal rounds of TLS
and anisotropic reﬁnement. The ligands in the crystals were
modelled into difference Fourier maps phased by the reﬁned
unliganded structures. Solvent molecules were added to the
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Table 3
Data-collection and reﬁnement statistics.
Values in parentheses are for the highest resolution shell.
Data set C65A C65A C65A C65A/K59A C65A/K59A C65A/K59A C65A/W54F C65A/W112F C65A/W54F/W112F
Space group P6122 P1 P41 P212121 P41 P41 P1 P1 P1
Crystal form 1 2 3 4 5 6 7 8 9
Unit-cell parameters
a (A˚) 60.78 43.13 91.13 38.33 90.97 67.38 41.62 42.25 42.51
b (A˚) 60.78 45.82 91.13 57.63 90.97 67.38 45.87 46.25 46.62
c (A˚) 178.77 49.15 36.81 131.80 36.74 287.67 48.26 47.78 47.89
 () 90.0 73.12 90.0 90.0 90.0 90.0 69.40 68.89 69.14
 () 90.0 82.82 90.0 90.0 90.0 90.0 77.67 77.15 77.10
 () 120 64.90 90.0 90.0 90.0 90.0 65.32 65.17 64.81
Molecules in the asymmetric unit 1 2 2 2 2 8 2 2 2
Resolution range (A˚) 30.0–1.40 40.03–1.40 45.56–1.55 57.63–1.66 28.77–1.60 50.0–1.80 45.04–1.75 26.08–1.40 33.73–1.69
Observed reﬂections 743727 129614 176101 140796 293569 481238 104994 226240 74160
Independent reﬂections 39501 60070 44187 34796 39985 117470 29286 57481 33458
Multiplicity 18.8 (12.8) 2.2 (2.2) 4.0 (3.9) 4.0 (4.2) 7.3 (7.2) 4.1 (4.1) 3.6 (3.6) 3.9 (3.9) 2.2 (2.1)
Rmerge† (%) 6.6 (32.1) 11.8 (33.4) 4.3 (35.4) 6.0 (35.3) 5.8 (30.9) 7.0 (6.1) 6.7 (35.2) 3.1 (38.3) 9.0 (20.5)
hI/(I)i 32.2 (6.4) 8.0 (2.1) 13.8 (3.3) 13.0 (3.7) 18.8 (5.9) 11.2 (2.6) 10.0 (3.4) 13.2 (3.5) 9.6 (5.0)
Completeness (%) 99.8 (99.7) 93.5 (91.9) 99.6 (99.7) 99.1 (99.4) 99.7 (100) 99.6 (100.0) 95.9 (95.0) 95.7 (94.4) 96.3 (94.8)
Reﬂections in reﬁnement 39409 60070 44155 34739 39967 117341 29212 57479 33458
Rcryst‡ (%) 21.41 24.98 20.82 20.13 19.88 20.79 19.58 22.06 19.43
Rfree§ (%) 23.27 27.99 23.49 23.98 22.61 24.89 23.28 24.56 23.24
Protein atoms 1262 2546 2492 2482 2482 10044 2548 2540 2534
Ligand atoms 45 5 76 81 152
Water molecules 102 192 84 120 106 142 105 87 135
R.m.s.d.}
Bond lengths (A˚) 0.004 0.005 0.004 0.004 0.004 0.005 0.004 0.008 0.004
Bond angles () 1.012 0.871 0.886 0.903 0.922 1.014 0.944 1.190 0.903
Planar groups (A˚) 0.004 0.004 0.003 0.003 0.003 0.004 0.004 0.007 0.004
Chiral volumes (A˚3) 0.033 0.062 0.063 0.062 0.063 0.070 0.068 0.082 0.065
Average B factor (A˚2)
Overall 22.31 17.00 28.60 19.59 25.75 43.25 39.00 25.30 14.23
Protein atoms 21.39 16.71 28.17 19.55 25.02 43.09 39.02 25.25 14.17
Ligand atoms 34.20 12.57 42.93 46.33 64.28
Solvent atoms 28.46 20.87 28.45 20.39 27.29 32.36 38.52 26.85 15.42
PDB code 4orr 4ors 4oru 4orw 4orx 4ory 4os0 4os3 4os8
† Rmerge =
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ, where hI(hkl)i is the mean intensity of the i observations of reﬂection hkl. ‡ Rcryst =
P
hkl

jFobsj  jFcalcj

=
P
hkl jFobsj, where
|Fobs| and |Fcalc| are the observed and calculated structure-factor amplitudes, respectively. Summation includes all reﬂections used in the reﬁnement. § Rfree =P
hkl

jFobsj  jFcalcj

=
P
hkl jFobsj evaluated for a randomly chosen subset of 5% of the diffraction data not included in the reﬁnement. } Root-mean-square deviation from ideal
values.
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models in the ﬁnal stages of reﬁnement according to
hydrogen-bond criteria and only if their B factors reﬁned to
reasonable values and if they improved the Rfree.
The diffraction data and reﬁnement statistics of all of the
models are summarized in Table 3. The ﬁnal R factors and
r.m.s. deviations in Table 3 were calculated with phenix.reﬁne
(Afonine et al., 2005; Davis et al., 2007).
2.6. Fluorometric titrations
All measurements were conducted with
an FP 8200 spectroﬂuorometer (Jasco,
Easton, Maryland, USA) with the samples
at room temperature. L-PGDS (1 mM) in
20 mM Tris–HCl pH 7.5 buffer was titrated
with 0.5 ml injections of the crystallization
solution of crystal form 3 consisting of 0.2M
ammonium sulfate, 30%(w/v) PEG 4000.
Fluorescence emission spectra were
acquired with 5 nm width excitation and
emission slits. The excitation wavelength
was 295 nm and emission was recorded in
the 305–500 nm range. Data were analyzed
using SigmaPlot v.9.0 (Systat Software Inc.,
San Jose, California, USA).
2.7. Isothermal titration calorimetry
The diluted (1:100) precipitating solution
of crystal form 3 consisting of 2 mM
ammonium sulfate, 0.3%(w/v) PEG 4000
was titrated with the protein solution. The
protein was dissolved to a concentration of
9 mM in 20 mM Tris–HCl pH 7.5, 0.15M
NaCl. The titrations were performed at 25C
using a Nano ITC instrument (TA Instru-
ments, New Castle, Delaware, USA). A total
of 25 injections of 2 ml aliquots of the
protein titrating solution were added under
stirring with 5 min intervals to the 300 ml
PEG solution cell. The heat of the injections
was corrected for the heat of dilution of the
protein into the PEG solution. Three repli-
cates were performed. The data were
analyzed using NanoAnalyze (TA Instru-
ments, New Castle, Delaware, USA).
2.8. Analysis of the models
The superposition of the models matching
the secondary structure was performed
using the SSM Superposition subroutine of
Coot (Krissinel & Henrick, 2004). The
distances between the ligand, PEG and
protein atoms were calculated with the
CCP4 program CONTACT (Tadeusz Skar-
zynski, Imperial College, London). Structu-
rally invariant water molecules were
identiﬁed using the web-based program
3d-SS (http://cluster.physics.iisc.ernet.in/3dss/;
Sumathi et al., 2006). Figures of the
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Figure 1
Apo and holo crystals of the C65Amutant of human L-PGDS. (a) Stereo diagram representing
a human L-PGDS monomer. The ﬁgure was prepared with the coordinates of crystal form 1
(L-PGDS bound to PEG). The eight strands of the -sheet are identiﬁed with the letters A–H
and the position of the active-site Cys65 is indicated in red. The side chains of the mutated
amino acids are represented in yellow and blue and the blue dot identiﬁes the position of the
conserved water molecule. Only the four loops at the entrance of the barrel are indicated in the
ﬁgure: L1, A–B; L3, C–D; L5, E–F; L7, G–H. Note the presence of the helix in the ﬁrst loop L1.
(b) The asymmetric unit of the apo form of the C65A mutant, crystal form 2. In the ﬁgure the
loops L5 and L7 of monomer A are coloured green and red, respectively. (c) Stereoview of the
unliganded monomer A of crystal form 2 of the C65A mutant of human L-PGDS and the
mutant bound to PEG in crystal form 1. The apo form of the protein is in blue and the molecule
with PEG in the cavity is in green. Note the important difference in the ﬁrst helix of loop L1.
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structures were prepared and rendered with PyMOL (http://
www.pymol.org).
3. Results
3.1. General features of the structures
As expected, all of the mutants present the classical lipo-
calin fold. We have chosen crystal form 1, i.e. a crystal of the
C65A mutant, which was the ﬁrst structure that we solved,
diffracts to 1.4 A˚ resolution and contains one molecule in the
asymmetric unit, to deﬁne the secondary-structure elements.
The ﬁnal L-PGDS model in this crystal form spans the
sequence from Val28 to Thr188. In the current standard
notation that we use residues 1–22 are the signal peptide, so
the mature polypeptide chain spans residues 23–190. The
model includes 1262 protein atoms, one sulfate, a PEG
molecule and 102 water molecules. No clear electron density is
present for the ﬁrst ﬁve and the last two residues, and partially
disordered regions with discontinuous electron density are
found between Ala72 and Gly75 and between Arg85 and
Gln88. The conventional R factor for all data to a resolution of
1.40 A˚ is 21.3% and the free R factor is 23.2% (Table 3).
91.5% of the residues are in the most favourable region of the
Ramachandran plot and 7.1% are in the additionally allowed
region. Tyr125 and Ser114 are in disallowed regions of the
plot. An equivalent of the ﬁrst of these two amino acids is
typically found in disallowed regions in lipocalins, whereas the
distortion in the second is probably owing to the presence of
the PEGmolecule bound in the crystals since it is absent in the
apo form (crystal form 2) and in crystal form 3, in which the
PEG molecule adopts a slightly different conformation. The
overall fold consists of the canonical -barrel with eight
strands of antiparallel -chain with a ﬁrst short -helix in the
loop between strands A and B and a second longer -helix
packed against the barrel. The ﬁnal secondary-structure
assignments are as follows for the -strands: strand A, residues
41–50; strand B, residues 63–71; strand C, residues 77–85;
strand D, residues 88–98; strand E, residues 104–108; strand F,
residues 115–123; strand G, residues 128–137; strand H, resi-
dues 144–150. The two -helices span residues 53–60 and 157–
169. In addition, a very short -strand spanning residues 177–
179 and three 310-helices spanning residues 36–39, 139–142
and 174–176 were also identiﬁed. The opening of the ligand-
binding site at one end of the L-PGDS model has four loops
joining strands A and B (L1), C and D (L3), E and F (L5) and
G and H (L7). The other three loops (L2, L4 and L6) are at the
opposite closed end of the molecule (Flower et al., 2000).
Fig. 1(a) shows a stereo diagram of the L-PGDS molecule that
identiﬁes the elements of secondary struc-
ture, Cys65 and the four loops that control
access to the ligand-binding cavity.
3.2. Binding of polyethylene glycol to the
C65A mutant
In the structure of crystal forms 1 and 3 of
the C65A mutant, a very clear and contin-
uous electron density was found occupying
the ligand-binding cavity. It was interpreted
as a PEG molecule, a ligand that was also
found in the cavity of this molecule by Lim
et al. (2013). Crystal form 2, which contains
two monomers in the asymmetric unit, is the
apo form of this mutant. Although poly-
ethylene glycol was also present in the
mother liquor used to prepare these crystals
(see Table 2), PEG did not access the ligand-
binding cavity because the two monomers
present in the asymmetric unit pack with
loops L5 (residues 109–114) and L7 (resi-
dues 138–143) of one monomer blocking
access to the cavity of the other. The in-
accessibility of the cavity was conﬁrmed by
soaking experiments with these crystals.
Fig. 1(b) shows the packing of the two
monomers in the asymmetric unit of crystal
form 2, in which loops L5 and L7 of
monomer A are coloured green and red.
The two holo conformations in which
L-PGDS is bound to PEG in crystal forms 1
and 3 are very similar to each other and do
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Figure 1 (continued)
(d) A similar stereoview in which the two models superimposed are monomerA of crystal form
2 and monomer A of crystal form 3. The apo form of the protein is again shown in blue. Note
that the changes are very similar to those observed in the other crystal form. (e) Stereo diagram
showing a superposition of the polypeptide chains spanning residues 50–64 of molecule A of
crystal form 1 and molecule A of crystal form 2. The apo form of the protein is in blue and the
holo form is in red. The electron density, contoured at a 1.0 level, was represented for amino
acids 58–60 of both forms. In the holo form Lys59 is vertical while in the apo form it points in
the direction of the reader.
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not differ greatly from the apo conformation of crystal form 2.
Fig. 1(c) shows a stereo representation of the superimposed
structures of the apo form (blue) and the holo form (green)
of crystal form 1 and Fig. 1(d) shows a similar representation
with the holo form of crystal form 3 (red). In both cases the
main difference is in loop L1, in which the ﬁrst helix is less
structured and shorter in the apo form, in which the electron
density is less clear and in some sections discontinuous. As a
consequence, the models of the two molecules in the asym-
metric unit of the apo protein in crystal form 2 present some
differences in this area, with molecule B being more similar to
the holo form. Fig. 1(e) examines in detail L1, the area where
the apo–holo differences are more substantial. The secondary
structures of molecule A of crystal form 1 and molecule A of
crystal form 2 were superimposed and the models and electron
densities of the polypeptide chains spanning residues 50–64
were represented in stereo. Note the position of Lys59 in the
apo and holo forms. The side chain points towards the interior
of the cavity in the holo form and towards the outside in the
apo form. In the other molecule of the asymmetric unit of the
apo form the apo–holo differences are not as important.
The electron density assigned to PEG in crystal form 3 is
very clear and extends from one molecule into the second
molecule present in the asymmetric unit, thus deﬁning a
pseudo-dimer in which, although the two monomers are not
exactly equivalent, an approximate noncrystallographic
twofold axis is evident, as shown in Fig. 2(a). The molecular
weight of the PEG molecule ﬁtted to the experimental elec-
tron density is 1117, i.e. the model of the molecule is shorter
than the most abundant species present in the crystallization
mother liquor. The presence of electron density corresponding
to a lower molecular-weight species could be owing to either
disordered density in the crystals or to the binding of a lower
molecular-weight polymer present in the crystallization
Table 4
Hydrophobic contacts with PEG molecules.
Crystal form 1 Crystal form 3 Crystal form 5 Crystal form 6
Leu48 B F
Trp54 A A E
Leu55 A A, B A, B E, F, G, H
Ala59 G
Leu62 A A, B A, B F, H
Met64 A A, B
Leu79 A A, B A F
Phe83 A A, B
Met94 A A, B A, B E, F, G, H
Trp112 A A, B A, B E, F, G
Val118 A A, B E, F, G
Phe143 A A, B A, B E, F, G, H
Met145 A A, B A, B E, G, H
Figure 2
Binding of polyethylene glycol to the C65A mutant of human L-PGDS. (a) Electron density of the PEG molecule in the asymmetric unit of crystal form
3. The approximate twofold axis is perpendicular to the plane of the ﬁgure. The 2Fobs  Fcalc map was contoured at the 1.0 level. (b) Fluorometric
titration of human L-PGDS with PEG. The titration curves were obtained by adding 0.5 ml injections of a 30% PEG 4000 solution to a 1 mM sample of
L-PGDS in 20 mM Tris–HCl pH 7.5. The arrow indicates the progressive quenching in arbitrary units of the maximal ﬂuorescence emission. The inset
shows the ﬂuorescence quenching as a function of PEG 4000 concentration. (c) Isothermal titration calorimetry. The ﬁgure represents the titration curve
obtained with 2 ml injections of a 9 mM L-PGDS solution added to 300 ml of a 750 mM PEG solution. The raw data are shown in the top part of the ﬁgure
as a plot of corrected heat rate versus time. The line at the bottom represents the best ﬁt of the data assuming a stoichiometry of two L-PGDS molecules
per PEG molecule.
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mother liquor or to both factors. It is worth mentioning that a
very similar situation was described by Lim et al. (2013), who
used PEG 2000 MME in the crystallization mother liquor
but ﬁtted a PEG molecule of molecular weight 250. Many
hydrophobic interactions were identiﬁed in all of the crystal
forms that contain PEG bound in the central cavity. They are
all included in Table 4, in which the residues interacting with
PEG are listed along with the molecules in which the inter-
action was observed. It is also worth mentioning that its
electron density overlaps very well with that of the endo-
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Figure 3
The C65A/K59A double mutant. (a) Superposition of the C chain trace of the apo forms of the C65A (crystal form 2) and C65A/K59A (crystal form 4)
mutants. The single mutant is shown in blue and the double mutant in red. The most important differences are observed in loop L1, which contains the
ﬁrst -helix, and in the position of the side chains of Trp54 and Trp112, which are not in contact in the single mutant and move closer to each other in the
double mutant, approaching from a distance of about 9 A˚ to about 4–5 A˚. (b) Superposition of the C chain trace of the L-PGDS molecule bound to
PEG of the C65A (crystal form 1) and C65A/K59A mutants (crystal form 5). The single mutant is shown in green and the double mutant is again shown
in red. In the double mutant the ring of Phe143 moves to occupy space vacated by the absence of the lysine side chain. (c) Electron density of the PEG
molecule curling around the Lys59 side chain (crystal form 1). The 2Fobs  Fcalc map was contoured at the 1.0 level. (d) Binding of PEG to the double
mutant C65A/K59A. Note the position of the mutated Ala59. The orientation of the four ﬁgures is approximately the same. The 2Fobs  Fcalc was
contoured at the 1.0 level.
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genous fatty acids observed by Zhou et al. (2010), so that the
PEG–L-PGDS structure can be considered to be one of the
holo structures of the enzyme.
The interaction of L-PGDS with PEG was conﬁrmed by
ﬂuorometric titrations and isothermal titration calorimetry.
After trying several alternatives, in both cases it was found
that ﬁtting of the data could be best performed assuming a
stoichiometry of two protein molecules bound to a single PEG
unit, in agreement with the crystallographic data.
Fig. 2(b) shows a representative ﬂuorometric titration of a
L-PGDS sample with the solution used to prepare crystal form
3. The ﬁgure represents the titration curves obtained with
0.5 ml injections of the crystallization solution. Every curve
was normalized against a solution consisting of 20 mM Tris–
HCl pH 7.5 (PGDS buffer) titrated with the same volume of
crystallization solution. The arrow indicates the progressive
quenching of the maximal ﬂuorescence emission owing to the
addition of PEG 4000 and the inset shows the ﬂuorescence
quenching as a function of PEG 4000 concentration, which can
be used to obtain a Kd of 215 mM.
Fig. 2(c) reports the experimental ITC data in a corrected
heat rate versus time plot. The bottom of the ﬁgure shows
the normalized ﬁt assuming a stoichiometry of two L-PGDS
molecules per PEG molecule (as observed in the crystals).
The ﬁgure represents the titration curves obtained with 2 ml
injections of a 9 mM L-PGDS solution added to 300 ml of the
diluted precipitating solution (750 mM in PEG 4000). Analysis
of the data yields a dissociation constant Kd of 210 mM, which
is in very good agreement with the ﬂuorometric result. The
apparent difference between the initial portion of the ITC and
the ﬂuorometric curves is simply owing to the use of larger
aliquots of the titrant in ﬂuorimetry, which was necessary to
produce an observable signal.
3.3. The C65A/K59A double mutant
The C65A/K59A double mutant was prepared because
mutation of Lys59, one of the few conserved charged residues
in the external part of the ligand-binding cavity, to Ala was
found to increase the catalytic efﬁciency of the enzyme (Zhou
et al., 2010), a fact that could be explained by its involvement
in entrance/exit of the ligands to/from the cavity. A compar-
ison of the position of this side chain in crystal forms 1 and 2
reveals that in the molecule bound to PEG the residue points
towards the inside and is in close hydrophobic contact with the
ligand, while in the apo forms it is found pointing towards the
outside of the cavity. The double mutant was crystallized in
three different space groups, crystal forms 4, 5 and 6, the ﬁrst
with no ligand in the cavity and the second and third with PEG
bound. Although in the apo form of the double mutant the
molecules pack differently from those of the single mutant
C65A (crystal form 2), access to the cavity is equally impeded
by the presence of lattice interactions with symmetry-related
molecules in both molecules in the asymmetric unit. Fig. 3(a)
compares the C chain trace of the apo forms of the C65A and
C65A/K59A mutants. The single mutant is shown in blue and
the double mutant is shown in red. The most noticeable
differences are found in loop L1, which contains the ﬁrst eight-
amino-acid helix, and in the position of the side chains of
Trp54 and Trp112, which are not in contact in the single
mutant and become closer to each other in the double mutant,
with their shortest distance changing from about 9 A˚ to about
4–5 A˚. Since the packing of the molecules in the two different
crystal forms involves these areas, these differences cannot be
ascribed to the absence of the Lys chain in the cavity but might
be owing to different packing in the two different space
groups.
The chain traces of the single and double mutant bound to
PEG are compared in Fig. 3(b), in which the double mutant is
again shown in red while the single mutant is shown in green.
Note that while the positions of the side chains of the two
tryptophans in the ﬁgure, Trp54 and Trp112, are not very
different in the single and double mutants, the ring of Phe143
in the double mutant points towards the interior of the cavity,
probably to occupy space left vacant by the lysine side chain.
The electron density of the side chain of Lys59 is shown in
Fig. 3(c) and it is found to be in close contact with the PEG
molecule that curls around it. Fig. 3(d) shows the binding of
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Table 5
Solved X-ray structures of L-PGDS.
Mutant C65A C65A C65A C65A C65A
Wild type
(apo)
Wild type
(co-crystals)
Species Mouse Mouse Human Human Human Human Human
Space group P212121 C2221 P6122 P41 P6122 P212121 P212121
Unit-cell parameters
a (A˚) 46.2 46.3 60.5 90.2 61.0 36.4 36.2
b (A˚) 66.8 67.1 60.5 90.2 61.0 56.4 56.4
c (A˚) 105.3 104.6 177.2 35.6 179.5 73.0 72.9
 () 90.0 90.0 90.0 90.0 90.0 90.0 90.0
 () 90.0 90.0 90.0 90.0 90.0 90.0 90.0
 () 90.0 90.0 120.0 90.0 120.0 90.0 90.0
Molecules in the
asymmetric unit
2 1 1 2 1 1 1
Resolution range (A˚) 56.8–2.10 10.0–2.00 20.0–1.66 50.0–1.70 30.5–1.40 44.6–2.09 44.6–1.88
PDB code 2czt 2czu 3o19 3o2y 3o22 4imn 4imo
Reference Kumasaka et al.
(2009)
Kumasaka et al.
(2009)
Zhou et al. (2010) Zhou et al. (2010) Zhou et al. (2010) Lim et al. (2013) Lim et al. (2013)
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PEG in the double mutant. The absence of contacts with the
Lys gives more freedom of movement to the PEG molecule
and thus less deﬁned electron density is observed for the areas
of the PEG molecule that were in contact with the Lys side
chain. The orientation of the ligand is very similar in the single
and double mutants. This additional freedom of movement
is reﬂected by a slightly higher dissociation constant for the
double mutant as determined by both ﬂuorometric titrations
and ITC. The ﬁrst method yields a dissociation constant for
the double mutant of Kd = 321 mM, whereas the second gives a
Kd value of 297 mM.
3.4. Mutants with tryptophan replaced by phenylalanine
Two of the three Trp residues present in human pros-
taglandin D synthase are present at the entrance of the cavity
that harbours the ligand-binding site and enzyme active site:
Trp54 and Trp112. The third tryptophan, Trp43, is in -strand
A and has very clear electron density in
the C65A mutant in an area on the
surface of the molecule, and its plane is
in hydrophobic contact with Phe39,
which is more internal, and also with
Arg51, which is more superﬁcial. In the
mutants in which the tryptophans at the
entrance of the cavity were substituted
by phenylalanines, the electron density
of residue 43 is equally well deﬁned.
Phenylalanine was selected to replace
the two tryptophans because it was
assumed to be a less perturbing change
from a structural point of view despite
the fact that the two amino acids are
known to behave quite differently
(Braun & von Heijne, 1999).
Two double mutants, C65A/W54F
and C65A/W112F, and a triple mutant
with the two tryptophans replaced by
two phenylalanines were prepared. The
crystallographic data listed in Table 3
shows that the three crystal forms,
although growing under different
conditions, are virtually isomorphous.
The three crystal forms are also closely
related to crystal form 2, the apo form
of the single mutant C65A. In fact,
monomer A of crystal form 2 can be
superimposed on monomer A of the
triple mutant (crystal form 9) by the
rotation  = 8.17,  = 1.90,  = 8.92
and the translation x = 0.32 A˚,
y = 0.21 A˚, z = 0.27 A˚. The ligand-
binding site of these mutants is thus
blocked by the packing of the molecules
in the crystals, a fact that was conﬁrmed
by soaking experiments with several
ligands.
The two tryptophans at the entrance to the cavity are found
in loops L1 (Trp54) and L5 (Trp112) and the electron density
of the phenyl rings is less well deﬁned than that of the indole
rings in the nonmutated structures. Interestingly, in the
mutants in which only one phenylalanine was introduced the
electron density of the remaining indole ring is also more
poorly deﬁned. Mutation of only one of the two tryptophans
causes a displacement of both side chains and the ﬁnal posi-
tion adopted by the mutated phenylalanine ring and the
nonmutated indole is very similar independently of which of
the two residues was changed. Fig. 4(a) is a superposition of
the C chain trace of the C65A mutant (green), the C65A/
W54F double mutant (blue) and the C65A/W112F double
mutant (red). Note that the ring of Phe143 remains in virtually
the same position in all three mutants. Its electron density is
very well deﬁned in both the two double mutants and the
triple mutant. Fig. 4(b) shows the superposition of the single
C65A mutant and the triple C65A/W54F/W112F mutant. The
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Table 6
Comparison of ligand-binding sites of L-PGDS mutants.
Mutant
Crystal
form
Space
group Monomer Ligand
Volume 1,
CASTp (A˚3)
Volume 2,
CASTp (A˚3)
Volume 1,
POCASA (A˚3)
C65A 1 P6122 A PEG 461.2 4.5 446
C65A 2 P1 A None 879.6 6.1 750
C65A 2 P1 B None 606.8 852
C65A 3 P41 A PEG 466.3 1.7 391
C65A 3 P41 B PEG 430.8 2.2 469
C65A/K59A 4 P212121 A None 502.3 4.0 538
C65A/K59A 4 P212121 B None 500.7 2.9 499
C65A/K59A 5 P41 A PEG 525.9 1.7 494
C65A/K59A 5 P41 B PEG 313.9 1.6 542
C65A/K59A 6 P41 A None 640.1 2.9 439
C65A/K59A 6 P41 B None 332.7 1.8 419
C65A/K59A 6 P41 C None 445.2 3.2 384
C65A/K59A 6 P41 D None 501.8 441
C65A/K59A 6 P41 E PEG 517.7 4.4 501
C65A/K59A 6 P41 F PEG 548.1 4.1 477
C65A/K59A 6 P41 G PEG 377.5 1.9 439
C65A/K59A 6 P41 H PEG 563.8 2.3 490
C65A/W54F 7 P1 A None 1060.2 0.7 920
C65A/W54F 7 P1 B None 629.4 0.7 367
C65A/W112F 8 P1 A None 860.1 1.1 605
C65A/W112F 8 P1 B None 952.4 1.0 396
C65A/W54F/W112F 9 P1 A None 891.5 0.6 732
C65A/W54F/W112F 9 P1 B None 329.7 2.7 423
Table 7
Ligand-binding site volume and conserved water molecules of other L-PGDS structures.
Solvent-accessible volume of the binding cavity calculated with CASTp (Liang et al., 1998) considering
only protein atoms.
Mutant Species
Space
group Monomer Ligand
Volume
1 (A˚3)
Volume
2 (A˚3)
Conserved
water
molecules
PDB
code
C65A Mouse P212121 A — 355.8 44.4 None 2czt
C65A Mouse C2221 A — 385.7 72.4 A190 2czu
C65A Mouse C2221 B — 465.8 76.7 B192 2czu
C65A Human P6122 A Fatty acids 324.6 4.6 A213 3o19
C65A Human P41 A Fatty acids 458.4 0.4 A4 3o2y
C65A Human P41 B Fatty acids 445.3 2.6 B200 3o2y
C65A Human P6122 A Fatty acids 429.9 6.9 A2 3o22
Wild type Human P212121 A PEG 588.2 0.8 A306 4imn
Wild type Human P212121 A Substrate analogue 1086.1 — A310 4imo
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position of the two mutated phenylalanine rings is very similar
to that adopted by the rings of the mutants in which only one
tryptophan was changed.
4. Discussion
The space groups, resolutions and PDB codes of the crystal
structures of lipocalin-type prostaglandin D synthase available
to date are listed in Table 5. Two correspond to the wild-type
human enzyme and the other ﬁve to the C65Amutant; the ﬁrst
two published were of the mouse enzyme and the other three
are of the human enzyme bound to palmitic and oleic acid. All
of the molecules that we have examined contain the C65A
mutation, and in addition we have introduced mutations in
other residues that are expected to play a role in the entrance/
exit of the ligands to/from the cavity. Our crystal form 1 is very
similar to crystal forms 1 and 3 of Zhou et al. (2010), but in our
crystals L-PGDS does not have fatty acids bound but instead
has PEG. Analogously, our crystal form 3 is very similar to
crystal form 2 of Zhou et al. (2010) and again PEG occupies
the place of the fatty acids. The apo form of this conformation
is our crystal form 2, in which there is no ligand bound to the
L-PGDS molecule and access to the cavity is prevented by the
packing of the molecules in the crystals. Figs. 1(c) and 1(d)
compare the two holo forms that we have examined with the
apo form of the same single mutant. The holo forms in the two
crystals are very similar to one another and differ from the apo
form in loop L1, in which the ﬁrst helix in the molecule is less
structured and shorter in the apo form.
The solvent-accessible volume of the ligand-binding cavity
of all of the molecules present in the nine crystal forms that we
have studied were calculated with CASTp (Liang et al., 1998)
and POCASA (Yu et al., 2010). The results of these calcula-
tions are listed in Table 6 for the structures that we present
here. As the table shows, the values obtained with the two
methods do not always correlate completely. The ﬁrst program
identiﬁed a larger more external and a smaller more internal
cavity in most cases. The deﬁnition of the two cavities corre-
sponds to those in mouse L-PGDS and the ﬁve hydrophobic
amino acids that were identiﬁed to separate them (Kumasaka
et al., 2009) are conserved in the sequence of the human
protein. Four of the ﬁve residues, Leu96, Val118, Leu131 and
Tyr149, superimpose quite well, while the ﬁfth, Leu79, points
more towards the interior of the second cavity in human
L-PGDS. The results in the table indicate that the packing of
the molecules inﬂuences the accessible volume and the two
members of an asymmetric unit of the apo forms (crystal
forms 2, 7, 8 and 9) do not show comparable values. There is a
substantial variability in the different crystals, but in general it
can be said that the holo forms tend to have smaller cavity
volumes, suggesting that the protein tends to establish tight
contacts with the ligand. Although the volume of the cavities
of the apo forms of the mutants varies substantially depending
on the position of the molecule in the crystal lattice and the
variable position of the loops at the entrance, in general the
cavities of the apo forms are somewhat larger than those of the
protein bound to PEG.
Fig. 5(a) shows a stereo diagram of three models with
different cavity volumes superimposed. The models are those
of the apo and holo forms of the C65A/K59A double mutant
and the apo form of the C65A/W54F double mutant, which
research papers
Acta Cryst. (2014). D70, 2125–2138 Perduca et al.  Mutants of human lipocalin-type prostaglandin D synthase 2135
Figure 4
Mutants with tryptophan replaced by phenylalanine. (a) Superposition of
the C chain traces of the C65Amutant (green, crystal form 2), the C65A/
W54F double mutant (blue, crystal form 7) and the C65A/W112F double
mutant (red, crystal form 8). Note that the ring of Phe143 remains in
virtually the same position in all three mutants. (b) Superposition of the
C chain traces of the C65A mutant (green, crystal form 2) and the triple
mutant C65A/W54F/W112F (red, crystal form 9). The position of the two
mutated phenylalanine rings is the same as that adopted by the rings of
the mutants in which only one tryptophan was changed.
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has the largest cavity volume (Table 6). Figs.
5(b) and 5(c) represent the smallest and the
largest cavity volumes as contact surfaces
deﬁned as indicated in the ﬁgure caption.
The holo form of the C65A/K59A mutant is
shown in red (Fig. 5b) and the apo form of
the C65A/W54F double mutant is shown in
green (Fig. 5c).
In agreement with our results, small-angle
X-ray scattering (SAXS) experiments with
the apo form of the C65A mutant of mouse
L-PGDS and its complexes with hydro-
phobic ligands have shown that the binding
of a lipophilic ligand induces a reduction of
the radius of gyration in the holo form of the
enzyme; this is in contrast to the radii of
gyration of -lactoglobulin and retinol-
binding protein, which remain almost the
same before and after ligand binding (Inoue
et al., 2009). The important inﬂuence of the
packing in the crystals on the cavity volume
is also shown by the variability observed in
the eight molecules present in the asym-
metric unit of crystal form 6. In this crystal
form, which diffracted to a somewhat lower
resolution, the electron density of the
ligands was not as clear as in the other forms
and therefore a model for PEG was included
in only four of the eight molecules in the
asymmetric unit: E, F, G and H.
Mutation of either one or two trypto-
phans at the entrance of the cavity does not
appear to substantially change the volumes
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Figure 5
The ligand-binding cavity in the mutants. (a) Stereo
diagram showing three models with different cavity
volumes superimposed. The models are those of
the double mutant holo C65A/K59A (monomer B,
crystal form 5, red, volume 1 = 313.9 A˚3, volume 2 =
1.6 A˚3), the apo C65A/K59A mutant (monomer A,
crystal form 4, blue, volume 1 = 502.3 A˚3, volume 2 =
4.0 A˚3) and the C65A/W54F double mutant
(monomer A, crystal form 7, green, volume 1 =
1060.2 A˚3, volume 2 = 0.7 A˚3). (b) Stereo diagram
showing the cavity of the double mutant holo C65A/
K59A (monomer B, crystal form 5). The transparent
orange surface represents the approximate size of
the internal cavity, 313.9 + 1.6 A˚3, deﬁned by a
sphere of 1.4 A˚ radius. (c) Stereo diagram showing
the cavity of the double mutant apo C65A/W54F
(monomer A, crystal form 7). The transparent
surface represents the approximate size of the
internal cavity, 1060.2 A˚3, deﬁned by a sphere of
1.4 A˚ radius. (d) Surface representation of the
ligand-binding cavity of the C65A mutant of human
L-PGDS. The ﬁgure was prepared with the coordi-
nates of the holo form in crystal form 1. PEG and
the conserved water molecule are shown in the
picture together with the amino acids that are
closest to them.
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of the cavities since, as pointed out above, changing one
tryptophan alters the position of the other and the ﬁnal
position of the new phenylalanines is virtually the same
regardless of whether or not the other tryptophan is mutated.
The main conclusion that can be drawn from similar
calculations for the crystal forms in Table 7 is that the ligand
cavity of mouse L-PGDS appears to be somewhat smaller than
that of the human counterpart, whereas the second, more
internal, cavity is larger in the mouse enzyme. The two main
factors that explain why the second cavity is smaller in the
human protein are the position of Leu79, which points
towards the second cavity in human L-PGDS, and the position
of the side chain of Phe39, which points towards the interior of
the cavity in human L-PGDS and is more superﬁcial in mouse
L-PGDS.
Examination of Table 3 shows that a total of 23 protein
molecules are present in the asymmetric units of the nine
crystal forms of the different mutants and that the resolution
of the data is sufﬁciently high to justify analysis of the position
of the water molecules in the cavities. When this is performed
it is found that there is one water molecule in approximately
the same position in virtually all of the available protein
cavities, with the exception of three monomers in crystal form
6, in which fewer solvent molecules were identiﬁed because
of the signiﬁcantly lower resolution of the data. It has been
labelled A501 in PDB entry 4orr.
Comparison of the location of this water molecule with
those in the other structures of L-PGDS listed in Table 5
reveals that the same position is occupied by water in all of the
human L-PGDS structures and in one of the mouse L-PGDS
structures. The molecule has been identiﬁed in Table 7, in
which the cavity volumes of the available structures calculated
with CASTp are also given.
The published crystal structures of H-PGDS show that
there are two water molecules located at the active site, one of
which is in proximity to Thr159 and Leu199; it coordinates
with inhibitors of the enzyme and appears to be in a position
that precludes replacement by an inhibitor atom (Trujillo et al.,
2012). The position of the conserved water molecule in
L-PGDS is shown in Fig. 5(d), which also gives the distances to
the OG atom of Thr147 and the O atom of Leu131. This ﬁgure,
which was prepared with the coordinates of the holo form in
crystal form 1, also shows the PEG molecule and suggests a
situation quite similar to that described for H-PGDS. Thus,
in spite of the fact that H-PGDS and L-PGDS have very
different three-dimensional structures and do not show any
sequence similarity, a conserved water molecule is found in the
proximity of two identical amino acids that coordinate the
solvent molecule in a very similar way.
To summarize, we can say that the holo forms (bound to
PEG) of the C65A mutant of human L-PGDS and of the
double mutant C65A/K59A are more compact than the apo
forms, a fact that may be attributed to conformational ﬂex-
ibility of the L-PGDS molecule, which is probably required by
the high versatility of the binding properties of the protein.
Examination of the apo forms of the double mutants C65A/
W54F and C65A/W112F and the triple mutant C65A/W54F/
W112F has revealed that mutation of one or both tryptophans
induces a similar displacement in the position of both side
chains, Trp54 and Trp112. In addition, we note that mutation
of Lys59 does not seem to affect the binding of PEG to the
ligand-binding cavity.
Taken together, our observations indicate that the residues
that we have mutated indeed appear to play a role in the
entrance/exit process of the substrate and/or other ligands
into/out of the binding cavity of the lipocalin. The role of a
conserved water molecule in the ligand-binding cavity iden-
tiﬁed in this study deserves further exploration.
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models and the structure factors of all of the crystal forms
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accession codes are given in Table 3. This work was supported
by Fondazione Cassa di Risparmio di Verona, Vicenza,
Belluno e Ancona.
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